Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: A randomized trial

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 1, 2001, Pages 19-25

  Jeremic, Branislav ^a   Shibamoto, Yuta ^b   Acimovic, Ljubisa ^a   Milicic, Biljana ^a   Milisavljevic, Slobodan ^a   Nikolic, Nebojsa ^a   Dagovic, Aleksandar ^a   Aleksandrovic, Jasna ^a   Radosavljevic Asic, Gordana ^c  

^a University Hospital

^b KYOTO UNIVERSITY   (Japan)

^c Institute for Lung Disease and TB   (Yugoslavia)

Author keywords

Carboplatin; Chemotherapy; Etoposide; Hyperfractionation; Non small cell lung cancer; Radiotherapy

Indexed keywords

CHEMOTHERAPY; FRACTIONATION; PULMONARY DISEASES; TUMORS;

MEDIAN SURVIVAL TIME;

RADIOTHERAPY;

CARBOPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TOXICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY; SURVIVAL RATE;

EID: 0035341566     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01546-7     Document Type: Article

References (35)

1. Improved survival of patients with unresectable non-small cell bronchogenic carcinoma by an innovated high-dose en bloc radiotherapeutic approach
2. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the Radiation Therapy Oncology Group
3. Radiotherapy and the management of locally advanced lung cancer of all cell types. Final report of randomised trial
4. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer; Mature results of a phase II trial
5. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer
6. Potential impact on survival of improved tumour downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer
7. Results of Cancer, and Leukemia Group B protocol 8935. A multi-institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer
8. Long-term follow-up of patients enrolled in a randomized trial comparing preoperative chemotherapy, and surgery with surgery alone in resectable stage III non-small-cell lung cancer
9. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma
10. Improved survival in stage III non-small-cell lung cancer; Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial
11. Radiation Therapy Oncology Group 88-08, and Eastern Cooperative Oncology Group 4588. Preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer
12. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15
13. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer; Radiation Therapy Oncology Group (RTOG) 92-04
14. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer; Radiation Therapy Oncology Group protocol 91-06
15. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer
16. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer
17. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer; A randomized study
18. Concurrent radiochemotherapy for patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a Phase II study
19. A new international staging system for lung cancer
20. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Treatment and Research of Cancer (EORTC)
21. Tables of the number of patients required in a clinical trial using the log rank test
22. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer
23. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer; A phase III trial of the cancer and Leukemia group B and the Eastern Cooperative Oncology Group
24. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
25. A randomized phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer; Final report of an Australian multi-centre trial
26. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 to 79.2 Gy - possible survival benefit with > 69.6 Gy in favorable patients with Radiation Therapy Oncology group stage III nonsmall cell lung carcinoma. Report of Radiation Therapy Oncology Group 83-11
27. Multidisciplinary approach to potentially curable non-small cell carcinoma of the lung
28. Phase I study of docetaxel with concomitant thoracic radiation therapy
29. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies
30. Gemcitabine and radiation therapy for non-small cell lung cancer
31. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer
32. Dose escalation for non-small cell lung cancer using conformal radiation therapy
33. Dosimetric verification of the dynamic intensity-modulated radiation therapy of 92 patients
34. Hyperfractionated radiation therapy with or without concurrent low-dose cisplatin in locally advanced squamous cell carcinoma of the head and neck; A prospective randomized trial